within Pharmacolibrary.Drugs.ATC.C;

model C03EB01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 1.6666666666666667,
    adminDuration  = 600,
    adminMass      = 0.04,
    adminCount     = 1,
    Vd             = 0.01,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0033333333333333335,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Combination diuretic containing furosemide, a potent loop diuretic, and a potassium-sparing agent (such as amiloride or triamterene). Used in the management of edema associated with heart failure, liver cirrhosis, or nephrotic syndrome, and in hypertension, particularly where hypokalemia prevention is important. Used and approved in many countries.</p><h4>Pharmacokinetics</h4><p>No dedicated population pharmacokinetic studies found for the specific fixed combination. Estimates are extrapolated based on the pharmacokinetics of individual agents (furosemide, amiloride/triamterene) in healthy adults following oral administration.</p><h4>References</h4><ol></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C03EB01;
